Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
Feature|Articles|October 9, 2026
- Pharmaceutical Executive: October 2026
- Volume 46
- Issue 8
The Future of Precision Medicine Depends on More Than Biology
Author(s)Ben Hargreaves
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
Advertisement
Advertisement
Precision medicine was once largely about making treatments more selective. From there, better structural understanding of biological targets allowed developers to design molecules that acted more precisely, as the evolution of JAK inhibitors for autoimmune disease in particular has demonstrated.
Related to this article
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
ESC 2026 marked a turning point — GLP-1s earn their first formal heart failure guideline recommendation and become a cardiometabolic platform.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Why purpose is becoming the most important infrastructure in AI-driven health care technology.
The future of engagement won’t be defined by how much information reaches health care professionals, but by how precisely it supports the decision at hand.
CORXEL’s Dr. Bo Liang on why GLP-1 therapies are a broader chronic disease platform — not just obesity drugs — with benefits across cardiovascular, renal, and metabolic disease.
Why GLP-1s achieving bariatric surgery-level efficacy is the field's most surprising advancement of the past decade.
Advertisement
Advertisement